Literature DB >> 15098231

Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients.

Bwee Tien Poll-The1, Jeannette Gootjes, Marinus Duran, Johannis B C De Klerk, Liesbeth J Maillette de Buy Wenniger-Prick, Ronald J C Admiraal, Hans R Waterham, Ronald J A Wanders, Peter G Barth.   

Abstract

The peroxisome biogenesis disorders (PBDs) with generalized peroxisomal dysfunction include Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD). There is clinical, biochemical, and genetic overlap among the three phenotypes, also known as Zellweger spectrum disorders. Clinical distinctions between the phenotypes are not sharply defined. Only limited sources are available to serve as a background for prognosis in PBD, especially in case of prolonged survival. We delineated the natural history of 31 PBD patients (age 1.2-24 years) through systematic clinical and biochemical investigations. We excluded classical ZS from our study, and included all patients with a biochemically confirmed generalized peroxisomal disorder over 1 year of age, irrespective of the previously diagnosed phenotype. The initial clinical suspicion, age at diagnosis, growth, development, neurological symptoms, organ involvements, and survival are summarized. Common to all patients were cognitive and motor dysfunction, retinopathy, sensorineural hearing impairment, and hepatic involvement. Many patients showed postnatal growth failure, 10 patients displayed hyperoxaluria of whom 4 had renal stones. Motor skills ranged from sitting with support to normal gait. Speech development ranged from non-verbal expression to grammatical speech and comprehensive reading. The neurodevelopmental course was variable with stable course, rapid decline with leukodystrophy, spinocerebellar syndrome, and slow decline over a wide range of faculties as outcome profiles. At the molecular level, 21 patients had mutations in the PEX1 gene. The two most common PEX1 mutations were the G843D (c.2528G-->A) missense and the c.2097insT frameshift mutation. Patients having the G843D/G843D or the G843D/c.2097insT genotypes were compared. Patients homozygous for G843D generally had a better developmental outcome. However, one patient who was homozygous for the "mild" G843D mutation had an early lethal disease, whereas two other patients had a phenotype overlapping with the G843D/c.2097insT group. This indicates that next to the PEX1 genotype other yet unknown factors determine the ultimate phenotype. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098231     DOI: 10.1002/ajmg.a.20664

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  29 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

2.  A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 degrees C.

Authors:  Avraham Zeharia; Merel S Ebberink; Ronald J A Wanders; Hans R Waterham; Alisa Gutman; Andreea Nissenkorn; Stanley H Korman
Journal:  J Hum Genet       Date:  2007-05-30       Impact factor: 3.172

3.  Zellweger Spectrum Disorder with Mild Phenotype Caused by PEX2 Gene Mutations.

Authors:  Andrea Mignarri; Claudia Vinciguerra; Antonio Giorgio; Sacha Ferdinandusse; Hans Waterham; Ronald Wanders; Enrico Bertini; Maria Teresa Dotti; Antonio Federico
Journal:  JIMD Rep       Date:  2012-01-29

4.  The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder.

Authors:  Shandi Hiebler; Tomohiro Masuda; Joseph G Hacia; Ann B Moser; Phyllis L Faust; Anita Liu; Nivedita Chowdhury; Ning Huang; Amanda Lauer; Jean Bennett; Paul A Watkins; Donald J Zack; Nancy E Braverman; Gerald V Raymond; Steven J Steinberg
Journal:  Mol Genet Metab       Date:  2014-01-23       Impact factor: 4.797

5.  Zellweger Syndrome Disorders: From Severe Neonatal Disease to Atypical Adult Presentation.

Authors:  David Cheillan
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Diagnostic and prognostic value of in vivo proton MR spectroscopy for Zellweger syndrome spectrum patients.

Authors:  H Rosewich; P Dechent; C Krause; A Ohlenbusch; K Brockmann; J Gärtner
Journal:  J Inherit Metab Dis       Date:  2016-08-03       Impact factor: 4.982

7.  Phytanic acid attenuates insulin-like growth factor-1 activity via nitric oxide-mediated γ-secretase activation in rat aortic smooth muscle cells: possible implications for pathogenesis of infantile Refsum disease.

Authors:  Gursev S Dhaunsi; Mayra Alsaeid; Saghir Akhtar
Journal:  Pediatr Res       Date:  2016-11-25       Impact factor: 3.756

8.  Mild Zellweger syndrome due to a novel PEX6 mutation: correlation between clinical phenotype and in silico prediction of variant pathogenicity.

Authors:  Małgorzata Rydzanicz; Teresa Joanna Stradomska; Elżbieta Jurkiewicz; Ewa Jamroz; Piotr Gasperowicz; Grażyna Kostrzewa; Rafał Płoski; Anna Tylki-Szymańska
Journal:  J Appl Genet       Date:  2017-10-18       Impact factor: 3.240

Review 9.  Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.

Authors:  Adeline Vanderver
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

10.  Infantile Refsum Disease: Influence of Dietary Treatment on Plasma Phytanic Acid Levels.

Authors:  Maria João Nabais Sá; Júlio C Rocha; Manuela F Almeida; Carla Carmona; Esmeralda Martins; Vasco Miranda; Miguel Coutinho; Rita Ferreira; Sara Pacheco; Francisco Laranjeira; Isaura Ribeiro; Ana Maria Fortuna; Lúcia Lacerda
Journal:  JIMD Rep       Date:  2015-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.